ProCE Banner Activity

How I Manage Treatment-Related Toxicity in Refractory Metastatic Colorectal Cancer

Clinical Thought
Treatment decisions in the refractory setting must consider the accumulated toxicities that patients have endured during previous rounds of therapy as well as the additional potential toxicities associated with the next treatment.

Released: July 01, 2016

Expiration: June 30, 2017

Share

Faculty

John L. Marshall

John L. Marshall, MD

Associate Professor, Hematology/Oncology
Department of Medicine
Georgetown University Hospital
Washington, DC

Provided by

Jointly provided by Postgraduate Institute for Medicine and Clinical Care Options, LLC
ProCE Banner

Supporters

This activity is supported by an educational grant from

Genentech Roche Virology

Faculty Disclosure

Primary Author

John L. Marshall, MD

Associate Professor, Hematology/Oncology
Department of Medicine
Georgetown University Hospital
Washington, DC

John L. Marshall, MD, has disclosed that he has received consulting fees, funds for research support, and funds for non-CME/CE services from Amgen, Bayer, Celgene, Genentech, and Taiho.